A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
Public ClinicalTrials.gov record NCT00116103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.
Study identification
- NCT ID
- NCT00116103
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2005
- Primary completion
- Not listed
- Completion
- Mar 31, 2006
- Last update posted
- Jun 6, 2012
2005 – 2006
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85251 | — |
| Not listed | Encinitas | California | 92024 | — |
| Not listed | Los Angeles | California | 90025 | — |
| Not listed | San Diego | California | 92120 | — |
| Not listed | San Jose | California | 95128 | — |
| Not listed | Denver | Colorado | 80206 | — |
| Not listed | Daytona Beach | Florida | 32114 | — |
| Not listed | Miami | Florida | 33176 | — |
| Not listed | Boise | Idaho | 83704 | — |
| Not listed | River Forest | Illinois | 60305 | — |
| Not listed | South Bend | Indiana | 46617 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | Missoula | Montana | 59804 | — |
| Not listed | Omaha | Nebraska | 68131 | — |
| Not listed | Cincinnati | Ohio | 45241 | — |
| Not listed | Oklahoma City | Oklahoma | 73120 | — |
| Not listed | Providence | Rhode Island | 02906 | — |
| Not listed | Spartanburg | South Carolina | 29303 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Madison | Wisconsin | 53792 | — |
| Not listed | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00116103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2012 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00116103 live on ClinicalTrials.gov.